SCHEMBL2532706

SCHEMBL2532706

CC(Br)CCCCCCCCCO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
TRPA1 O75762 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.36
SPHK1 Q9NYA1 2/20 0.34
LCK P06239 1/20 0.33
PPARD Q03181 1/20 0.33
ZDHHC20 Q5W0Z9 1/20 0.33
ZDHHC2 Q9UIJ5 1/20 0.33
CYP2D6 P10635 2/20 0.32
GMNN O75496 1/20 0.32
POLB P06746 1/20 0.32
THPO P40225 1/20 0.32
MTOR P42345 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26106679 1.00
SCHEMBL3873438 1.00 LMNA (0.41) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL3879426 1.00 LMNA (0.41) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL8172735 1.00 LMNA (0.41) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL96682 0.97
SCHEMBL4910631 0.88
SCHEMBL28927420 0.79 LMNA (0.38) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL3416469 0.79 TRPV1 (0.48) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL19783667 0.78 TRPV1 (0.46) LMNAALDH1A1TSHRTRPV1TRPA1
SCHEMBL3778363 0.77 LMNA (0.50) LMNAALDH1A1TSHRHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661502-B1 BIOSENSOR FOR DETECTING THE PRESENCE OF PROTEASES AND OPTIONALLY QUANTIFYING THE ENZYMATIC ACTIVITY THEREOF Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2016-03-09 EP disclosed
EP-2661502-A1 BIOSENSOR FOR DETECTING THE PRESENCE OF PROTEASES AND OPTIONALLY QUANTIFYING THE ENZYMATIC ACTIVITY THEREOF Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2013-11-13 EP disclosed
WO-2012093162-A1 BIOSENSOR FOR DETECTING THE PRESENCE OF PROTEASES AND OPTIONALLY QUANTIFYING THE ENZYMATIC ACTIVITY THEREOF COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2012-07-12 WO disclosed
US-20110256552-A1 METHOD FOR PREPARING A SUBSTRATE FOR IMMOBILIZING A CELL, SAID SUBSTRATE AND USES THEREOF UNIVERSITE VICTOR SEGALEN BORDEAUX 2 (FR) 2011-10-20 US disclosed
WO-2010000593-A1 BIOCHIPS FOR DETECTING THE ENZYMATIC ACTIVITY OF A PROTEASE ENZYME COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-01-07 WO disclosed
EP-2139999-A1 METHOD FOR PREPARING A SUBSTRATE FOR IMMOBILISING A CELL, SAID SUBSTRATE AND USES THEREOF Université Victor Segalen Bordeaux 2 (FR) 2010-01-06 EP disclosed
US-7491745-B2 Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease GEMIN X PHARMACEUTICALS CANADA INC. (CA) 2009-02-17 US disclosed
WO-2008125637-A1 METHOD FOR PREPARING A SUBSTRATE FOR IMMOBILISING A CELL, SAID SUBSTRATE AND USES THEREOF UNIVERSITE VICTOR SEGALEN - BORDEAUX 2 (FR) 2008-10-23 WO disclosed
US-20070037856-A1 e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide GEMIN X BIOTECHNOLOGIES INC. (CA) 2007-02-15 US disclosed
EP-1431286-A2 Prodigiosin derivatives for treating cancer or viral diseases Gemin X Biotechnologies Inc. (CA) 2004-06-23 EP disclosed
US-20030009032-A1 Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases GEMIN X PHARMACEUTICALS CANADA INC. (CA) 2003-01-09 US disclosed
EP-1255753-A2 PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS Gemin X Biotechnologies Inc. (CA) 2002-11-13 EP disclosed
WO-2001055131-A2 PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS GEMIN X BIOTECHNOLOGIES INC. (CA) 2001-08-02 WO disclosed
US-5620677-A CONTRAST AGENTS IN DIAGNOSTIC RADIOLOGY STERLING WINTHROP INC. (US) 1997-04-15 US disclosed
US-5607660-A X-RAY CONTRAST AGENTS FOR INTESTINES STERLING WINTHROP INC. (US) 1997-03-04 US disclosed
US-5531979-A X-RAY CONTRAST COMPOSITION STERLING WINTHROP INC. (US) 1996-07-02 US disclosed
EP-0609586-A2 Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract NYCOMED IMAGING AS (NO) 1994-08-10 EP disclosed
EP-0609587-A2 Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualization of the gastrointestinal tract NYCOMED IMAGING AS (NO) 1994-08-10 EP disclosed
US-5326553-A Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualization of the gastrointestinal tract STERLING WINTHROP INC. (US) 1994-07-05 US disclosed
US-5316755-A AQUEOUS X-RAY CONTRAST COMPOSITION FOR ORAL OR RECTAL ADMINISTRATION STERLING WINTHROP INC. (US) 1994-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030009032-A1 Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases POLI, PYCR1, ZC3HAV1 LMNA 3539/4885ALDH1A1 3326/4885TSHR 4715/4885
US-20070037856-A1 e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide POLI, PCNA, ELL LMNA 2969/4885ALDH1A1 2915/4885TSHR 4562/4885
US-20110256552-A1 METHOD FOR PREPARING A SUBSTRATE FOR IMMOBILIZING A CELL, SAID SUBSTRATE AND USES THEREOF FUS, NEFM, PIGS LMNA 484/4885ALDH1A1 1910/4885TSHR 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.